Replies to post #209134 on Biotech Values

[mcbio]

NTRP -

Since there is an active discussion with the recent trial news I thought to ask if anyone is familiar Neurotrope (NTRP, www.neurotropebioscience.com/ ) and/or their drug Bryostatin 1.

I have no investment interest at this time but would like to see something work in AD. They have data reporting in April from a 148 patient study in moderate to severe patients.

Here is the prior Phase 2a data: http://www.neurotropebioscience.com/Welcome_to_Neurotrope_BioScience/PressReleases-Mar-17-2015.html . And that essentially doesn't tell you much of anything. Patients got a single dose of the drug and there was no measurable improvement in cognition in mildly impaired patients. Not sure how that could give one confidence in the upcoming multi-dose Phase 2b data in moderate to severe patients.

Is there any strong independent data to suggest activating protein kinase C epsilon would work in AD?